Literature DB >> 17367445

Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.

Aksam A Yassin1, Farid Saad.   

Abstract

AIM: Late-onset hypogonadism is associated with relatively mild testosterone deficiencies. This study investigated the effects of restoring testosterone levels to normal in men with complaints of low sexual desire and erectile dysfunction. MAIN OUTCOME MEASURES: Sexual function was assessed with the International Index of Erectile Function (IIEF) at baseline and after 24 weeks of testosterone administration.
METHODS: Twenty-two hypogonadal men (mean age 58 years) with erectile dysfunction were studied. Fifteen patients had serum testosterone below 6.9 nmol/L, and seven between 7.2 and 11.7 nmol/L (reference values in our laboratory >/=12.0 nmol/L); there were considerable comorbidities. The duration of sexual complaints was on average 3.8 years. Patients received intramuscular long-acting testosterone undecanoate.
RESULTS: In all patients, serum testosterone levels were restored to normal within 6-8 weeks. Twelve patients reported a significant improvement in the sexual desire domain (from 4.5 to 8.4) and experienced an improvement in the erectile function domain (from 12 to 25 [Questions 1-5 plus 15)], following treatment with this long-acting testosterone; in 9 of 12 patients, this occurred only after at least 12-24 weeks. The remaining 10 patients reported an improvement of sexual desire (from 4.5 to 7.5), but no significant improvement in the erectile function domain (from 12 to 14). No changes in serum prostate-specific antigen or prostate volume were noticed while receiving this long-acting testosterone preparation.
CONCLUSION: Restoring testosterone levels to normal in men with proven subnormal testosterone levels improves libido in most subjects, and erectile function in more than 50% of these men. It may take 12-24 weeks before the effects of testosterone become manifest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367445     DOI: 10.1111/j.1743-6109.2007.00442.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  18 in total

1.  Correlation between serum total testosterone and the AMS and IIEF questionnaires in patients with erectile dysfunction with testosterone deficiency syndrome.

Authors:  Jae Kang; Byeong Kuk Ham; Mi Mi Oh; Je Jong Kim; Du Geon Moon
Journal:  Korean J Urol       Date:  2011-06-17

Review 2.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

3.  A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men.

Authors:  Jason Scovell; Ranjith Ramasamy; Jason R Kovac
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 4.  Testosterone supplementation therapy in the treatment of patients with metabolic syndrome.

Authors:  Jason R Kovac; Jason Kovac; Alexander W Pastuszak; Dolores J Lamb; Larry I Lipshultz
Journal:  Postgrad Med       Date:  2014-11       Impact factor: 3.840

Review 5.  Recent topics related to testosterone deficiency syndrome in Japan.

Authors:  Akira Tsujimura; Norio Nonomura
Journal:  Asian J Androl       Date:  2011-04-04       Impact factor: 3.285

6.  The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.

Authors:  Farid Saad; Louis J Gooren
Journal:  J Obes       Date:  2010-08-10

7.  Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.

Authors:  Jason R Kovac; Saneal Rajanahally; Ryan P Smith; Robert M Coward; Dolores J Lamb; Larry I Lipshultz
Journal:  J Sex Med       Date:  2013-11-06       Impact factor: 3.802

8.  Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.

Authors:  Prasanth N Surampudi; Christina Wang; Ronald Swerdloff
Journal:  Int J Endocrinol       Date:  2012-03-14       Impact factor: 3.257

Review 9.  Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido).

Authors:  Aksam A Yassin; Farid Saad
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

Review 10.  Onset of effects of testosterone treatment and time span until maximum effects are achieved.

Authors:  Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren
Journal:  Eur J Endocrinol       Date:  2011-07-13       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.